Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
View original at globenewswire.comPress Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a yearCablivi, t…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Qfitlia has the potential to make prophylaxis more accessible for people with hemophilia worldwide by offering effective bleed protection and simplified administration
80% confidenceThe approval of Qfitlia marks a true transition into a new era of non-factor prophylactic treatment for hemophilia in China
80% confidenceCablivi addresses a critical unmet need for patients facing aTTP/iTTP
80% confidenceQfitlia significantly reduces disease burden by requiring potentially just six subcutaneous injections annually, eliminating the need for frequent intravenous injections associated with traditional factor therapy
80% confidenceThese approvals highlight Sanofi's commitment to delivering meaningful innovation and improving outcomes for people living with rare diseases in China and around the world
80% confidenceQfitlia represents a potentially transformative advancement for the hemophilia community in China, shifting care from treating bleeds as they occur to helping prevent them altogether
80% confidence
Data points we hold from this source
| Sanofi · china approvals 2025 | 5 approvals |